Spotlight On... Germany's Xenios invests $2.6M in lung transplant specialist Xor-Labs Toronto; Medtronic gets EU OK for MRI-compatible defibrillators; Mitralign gets CE mark for novel functional mitral regurgitation treatment; and more...

Heilbronn, Germany's Xenios has invested $2.6 million in lung transplantation specialist Xor-Labs Toronto. Xor's Ex Vivo organ repair technology improves the quality of transplanted lungs. The company aims to reduce waiting times by expanding the number of lungs available for transplant. "The technology behind Xor's system has a long track record of clinical success. Over the past 6 years it has been used more than 200 times at UHN, approved by Health Canada, and clinical results using the technology have been extensively published, including in the prestigious New England Journal of Medicine," said Xor co-founder Dr. Shaf Keshavjee. "Xor's system will be a game-changer, since it will enable clinicians all around the world to use advanced techniques developed and perfected in Toronto, including gene and stem cell therapy, to make more lungs available for transplant and to make the transplanted lungs even better than the ones available today. All of this will improve patient care and reduce transplant waiting lists." Xenios makes devices that enable minimally invasive treatment of heart and lung failure. Release

@FierceMedDev: ICYMI Friday: FDA warns two diagnostics players for marketing unapproved tests. Article | Follow @FierceMedDev

@StacyALawrence: Philips unveils wearable, wireless vitals patch that goes from hospital to home. News | Follow @StacyALawrence

@VarunSaxena2: ICYMI from FierceDrugDelivery: Early-stage drug delivery implant targeting pancreatic cancer tumors showing promise. Story | Follow @VarunSaxena2

> Tiny micro-cap Calmare Therapeutics ($CTTC) got a $15 million, five-year contract with the U.S. military for its chronic neuropathic pain devices. More

> Medtronic ($MDT) got a CE mark for its line of cardiac resynchronization therapy defibrillators (CRT-Ds) for use with MRI scans. More

> Mitralign got a CE mark for its Mitralign Percutaneous Annuloplasty System (MPAS) to treat functional mitral regurgitation (FMR). More

Biotech News

@FierceBiotech: ICYMI Friday: Novartis' blood cancer drug bags a 'breakthrough' tag on the way to FDA filing. Article | Follow @FierceBiotech

@JohnCFierce: Chimerix scraps two PhIII trials as it regroups in wake of a setback. News | Follow @JohnCFierce

> Syndax readies its 2nd IPO attempt during a market tempest. News

> Amgen's osteoporosis drug 'romo' comes through with promising PhIII. Article

> Trevena snags a 'breakthrough' tag for its Phase III postoperative pain drug. More

Pharma News

@FiercePharma: Global group says Zika highlights need for research collaborations across specialties. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: New York gives $200M for Athenix to build Buffalo plant. Company pledges 900 jobs over 10 years. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Perrigo pushes forward with Ireland expansion as sales, earnings lag. Article | Follow @CarlyHFierce

> Merck CEO Frazier: Pharma needs to justify price hikes. Report

Animal Health News

> Aratana shoots for first European approval with canine arthritis drug. Report

> Global group says Zika highlights need for research collaborations across specialties. More

> U.K. charity sets out to sequence genomes from 50 dog breeds this year. Story

> Study: Fat cats will still love you if you put them on a diet. Item

> Pawprint looks to make its mark with EMR-based mobile app for pet owners. Article

Biotech IT News

> IBM strikes $2.6B deal for Truven to feed Watson's appetite for health data. News

> Ransomware becomes big business as hackers demand $3M to relinquish control of hospital files. Report

> Silicon Valley's biotech scene looks to bounce back from Theranos' 'black eye.' Story

> FDA tallies up 35 security incidents a month as hackers pursue stock-moving details. More

> Gamers crush algorithms in RNA structure design challenge. Article

Pharma Marketing News

> With LixiLan decision date set, Sanofi nears another head-to-head contest with Novo. Report

> Mylan gets one step closer to finally challenging Glaxo's Advair. Item

> Bayer's Aleve and GSK's Flonase top list of OTC TV ad spenders for 2015. Story

> Devicemakers give pharma a run for their money with new DTC ads. More

> Eylea may be giving Regeneron trouble in the U.S., but it's pumping up for Bayer in EU. Article